Fujirebio Announces Strategic Collaboration with Stanford Medicine to Advance Infectious Disease Research

TOKYO & SUNNYVALE, Calif.--(BUSINESS WIRE)--Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio’s Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test sensitivity can better inform treatment decisions in the clinic, as well as accelerate studies towards therapeutics and preventive strategies against infectious disease threats worldwide.

This collaboration represents a significant step forward in our mission to improve public health globally, by combining Fujirebio’s global IVD expertise and Fluxus’ ultrasensitive detection systems with Stanford’s world-renowned research.
Share

“Infectious diseases remain one of the greatest global health challenges of our time,” says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “By working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class scientific expertise, cutting-edge technology, and global health insights. This collaboration underscores our shared vision to create a healthier, more resilient world.”

“This collaboration represents a significant step forward in our mission to improve public health globally, by combining Fujirebio’s global IVD expertise and Fluxus’ ultrasensitive detection systems with Stanford’s world-renowned research,” says Dr. Peter Wagner, President and CEO of Fluxus, Inc. “We are thrilled to be working with Stanford University’s prestigious infectious disease experts.”

About Fujirebio

Fujirebio, a member of H.U. Group Holdings Inc., is an R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms. For more information, please visit http://www.fujirebio.com.

About Fluxus

Fluxus is an industry leader and innovator in optofluidic technologies that develops ultrasensitive detection systems and assay solutions to advance the diagnosis, monitoring, and treatment of diseases.

Contacts

H.U. Group Holdings, Inc.
For media:
Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884 　
Email: pr@hugp.com

For investors and analysts:
IR/SR Dept.
Phone: +81-3-6279-0926　
Email: ir@hugp.com

Industry:

Fujirebio

Details

Headquarters: Tokyo, Japan

Website: http://www.fujirebio.com

CEO: Goki Ishikawa

Employees: 1400

Organization: PRI

Release Versions

English Spanish Portuguese German French Italian (Summary)Dutch (Summary)Chinese Traditional Chinese Simplified

Hashtags

Contacts

H.U. Group Holdings, Inc.
For media:
Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884 　
Email: pr@hugp.com

For investors and analysts:
IR/SR Dept.
Phone: +81-3-6279-0926　
Email: ir@hugp.com

Social Media Profiles

Fluxus on LinkedIn

Fujirebio on LinkedIn

Fujirebio Europe on YouTube

More News From Fujirebio

Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries

MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological ma...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

GENT, Belgium & MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and bloo...

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

MALVERN, Pa., & TOKYO--(BUSINESS WIRE)--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the...

Back to Newsroom